Glycine vs Placebo for the Schizophrenia Prodrome

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborators: Glytech, Inc; National Alliance for Research on Schizophrenia and Depression
• Treatments: Glycine

Criteria

Inclusion Criteria:

• meet SIPS criteria for schizophrenia prodrome

Exclusion Criteria:

• history of psychosis